Recombinant human VEGF 165A protein (Active) is a Human Full Length protein, in the 27 to 191 aa range, expressed in Escherichia coli, with >98% purity, < 1 EU/µg endotoxin level and suitable for SDS-PAGE, FuncS, HPLC, CellDiff, CellAct.
Images
Publications
Filter by
- PloS one 17:e02767442022Peptide Lv augments intermediate-conductance calcium-dependent potassium channels (KCa3.1) in endothelial cells to promote angiogenesis.Applications:Unspecified applicationReactive species:Unspecified reactive speciesDylan L Pham,Autumn Niemi,Michael L Ko,Gladys Y P KoPubMed 36282858
- Open life sciences 17:1229-12392022Long non-coding RNA NEAT1 promotes angiogenesis in hepatoma carcinoma via the miR-125a-5p/VEGF pathway.Applications:Unspecified applicationReactive species:Unspecified reactive speciesJingyun Guo,Qi Yuan,Yuan Fang,Jinmao Liao,Zheng ZhangPubMed 36213383
- Molecular medicine reports 23:2020Hyperoxia sensitizes hypoxic HeLa cells to ionizing radiation by downregulating HIF‑1α and VEGF expression.Applications:Unspecified applicationReactive species:Unspecified reactive speciesDan Dong,Yan Fu,Feng Chen,Jing Zhang,Haiyan Jia,Jia Li,Huailin Wang,Jihong WenPubMed 33215223
- Acta ophthalmologica 98:e1-e122019Galectin-1 studies in proliferative diabetic retinopathy.Applications:Unspecified applicationReactive species:Unspecified reactive speciesAhmed M Abu El-Asrar,Ajmal Ahmad,Eef Allegaert,Mohammad Mairaj Siddiquei,Kaiser Alam,Priscilla W Gikandi,Gert De Hertogh,Ghislain OpdenakkerPubMed 31318490
- Nature communications 10:17312019CXCL4 assembles DNA into liquid crystalline complexes to amplify TLR9-mediated interferon-α production in systemic sclerosis.Applications:Unspecified applicationReactive species:Unspecified reactive speciesRoberto Lande et. al.PubMed 31043596
- Cellular physiology and biochemistry : internation 44:1251-12622017VEGF-A/Neuropilin 1 Pathway Confers Cancer Stemness via Activating Wnt/β-Catenin Axis in Breast Cancer Cells.Applications:Unspecified applicationReactive species:Unspecified reactive speciesLansheng Zhang et. al.PubMed 29179185
- Oncogene 35:4379-872016VEGF-A acts via neuropilin-1 to enhance epidermal cancer stem cell survival and formation of aggressive and highly vascularized tumors.Applications:Unspecified applicationReactive species:Unspecified reactive speciesD Grun et. al.PubMed 26804163
- Advanced healthcare materials 5:198-2042015LumeNEXT: A Practical Method to Pattern Luminal Structures in ECM Gels.Applications:Unspecified applicationReactive species:Unspecified reactive speciesJosé A Jiménez-Torres,Stephen L Peery,Kyung E Sung,David J BeebePubMed 26610188
- Oncology letters 9:945-9492015Extracts of endophytic fungus xkc-s03 from L. spica inhibit gastric cancer andApplications:Unspecified applicationReactive species:Unspecified reactive speciesJianan Tan,Haizhi Qi,Jiangdon NiPubMed 25624914
- The Journal of clinical endocrinology and metabolism 91:4603-112006Pituitary tumor transforming gene (PTTG) stimulates thyroid cell proliferation via a vascular endothelial growth factor/kinase insert domain receptor/inhibitor of DNA binding-3 autocrine pathway.Applications:Unspecified applicationReactive species:Unspecified reactive speciesD S Kim,J A Franklyn,K Boelaert,M C Eggo,J C Watkinson,C J McCabePubMed 16926250
Key facts
- Purity
- >98% SDS-PAGE
- Endotoxin level
- < 1 EU/µg
- Expression system
- Escherichia coli
- Tags
- Tag free
- Applications
- SDS-PAGE, FuncS, HPLC, CellDiff, CellAct
- Biologically active
- Yes
Amino acid sequence
A P M A E G G G Q N H H E V V K F M D V Y Q R S Y C H P I E T L V D I F Q E Y P D E I E Y I F K P S C V P L M R C G G C C N D E G L E C V P T E E S N I T M Q I M R I K P H Q G Q H I G E M S F L Q H N K C E C R P K K D R A R Q E N P C G P C S E R R K H L F V Q D P Q T C K C S C K N T D S R C K A R Q L E L N E R T C R C D K P R R
Consider this alternative
Reactivity data
| Application | Reactivity | Dilution info | Notes |
|---|---|---|---|
Application SDS-PAGE | Reactivity Reacts | Dilution info - | Notes - |
Application FuncS | Reactivity Reacts | Dilution info - | Notes - |
Application HPLC | Reactivity Reacts | Dilution info - | Notes - |
Application CellDiff | Reactivity Reacts | Dilution info - | Notes - |
Application CellAct | Reactivity Reacts | Dilution info - | Notes The protein can be used for dose-dependent stimulation of the proliferation of human umbilical vein endothelial cells (HUVEC) using a concentration range of 1.0-8.0 ng/ml. |
Associated Products
Select an associated product type
1 product for Alternative Product
Target data
Function
N-VEGF. Participates in the induction of key genes involved in the response to hypoxia and in the induction of angiogenesis such as HIF1A (PubMed:35455969). Involved in protecting cells from hypoxia-mediated cell death (By similarity). VEGFA. Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth (PubMed:34530889). Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. Binds to the NRP1/neuropilin-1 receptor. Binding to NRP1 initiates a signaling pathway needed for motor neuron axon guidance and cell body migration, including for the caudal migration of facial motor neurons from rhombomere 4 to rhombomere 6 during embryonic development (By similarity). Also binds the DEAR/FBXW7-AS1 receptor (PubMed:17446437). Isoform VEGF165B. Binds to the KDR receptor but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth.
Alternative names
VEGF, VEGFA, L-VEGF, Vascular permeability factor, VPF
Recommended products
Recombinant human VEGF 165A protein (Active) is a Human Full Length protein, in the 27 to 191 aa range, expressed in Escherichia coli, with >98% purity, < 1 EU/µg endotoxin level and suitable for SDS-PAGE, FuncS, HPLC, CellDiff, CellAct.
Key facts
- Purity
- >98% SDS-PAGE
- Endotoxin level
- < 1 EU/µg
- Expression system
- Escherichia coli
- Tags
- Tag free
- Applications
- SDS-PAGE, FuncS, HPLC, CellDiff, CellAct
- Biologically active
- Yes
- Biological activity
- Determined by its ability to stimulate the proliferation of human umbilical vein endothelial cells (HUVEC). The expected ED50 for this effect is 1.0-10.0ng/ml.
- Accession
- P15692-4
- Animal free
- No
- Species
- Human
- Reconstitution
- reconstitute with water at 100µL
- Concentration
Sequence info
Amino acid sequence
- A P M A E G G G Q N H H E V V K F M D V Y Q R S Y C H P I E T L V D I F Q E Y P D E I E Y I F K P S C V P L M R C G G C C N D E G L E C V P T E E S N I T M Q I M R I K P H Q G Q H I G E M S F L Q H N K C E C R P K K D R A R Q E N P C G P C S E R R K H L F V Q D P Q T C K C S C K N T D S R C K A R Q L E L N E R T C R C D K P R R
- Accession
- P15692
- Protein length
- Full Length
- Predicted molecular weight
- 38.2 kDa
- Amino acids
- 27 to 191
- Nature
- Recombinant
Specifications
- Form
- Lyophilized
- Additional notes
> 98% HPLC analyses. Sterile filtered
General info
- Function
N-VEGF
- Sequence similarities
Belongs to the PDGF/VEGF growth factor family.
- Post-translational modifications
Vascular endothelial growth factor A, long form
Storage
- Shipped at conditions
- Blue Ice
- Appropriate short-term storage duration
- 1-2 weeks
- Appropriate short-term storage conditions
- +4°C
- Appropriate long-term storage conditions
- -20°C
- Aliquoting information
- Upon delivery aliquot
- Storage information
- Avoid freeze / thaw cycle
This product is an active protein and may elicit a biological response in vivo, handle with caution.
Supplementary info
- This supplementary information is collated from multiple sources and compiled automatically.
- Activity summary
VEGF 165A or Vascular Endothelial Growth Factor 165A is an important protein that plays a role in angiogenesis which is the growth of new blood vessels. Also known as VEGF-A or VEGF isoform 165 this protein has a mass of around 23 kDa when it is in its biotinylated form. VEGF 165A is expressed in various cell types including endothelial cells which form the lining of blood vessels as well as in smooth muscle cells and certain tumor cells. The protein is often targeted in research using anti-VEGF antibodies.
- Biological function summary
This protein acts directly on endothelial cells to stimulate their proliferation and migration. VEGF 165A is part of a larger family of VEGF proteins that share similar structures and functions. It plays a critical role in both physiological processes like wound healing and pathological conditions like cancer where its expression becomes dysregulated. The protein can bind to receptors on the cell surface initiating cell signaling pathways that lead to angiogenesis.
- Pathways
VEGF 165A functions prominently in the VEGF signaling pathway and the MAPK/ERK pathway. Through these pathways it interacts with other proteins such as VEGF receptors particularly VEGFR-2 to propagate signals leading to angiogenesis and increased vascular permeability. These pathways are vital in ensuring that tissues receive an appropriate blood supply under various conditions including growth and repair processes.
- Associated diseases and disorders
VEGF 165A shows an association with cancer and age-related macular degeneration (AMD). Overexpression of VEGF 165A is linked to tumor growth because it helps form the blood vessels that supply the tumor known as tumor angiogenesis. Similarly in AMD abnormal blood vessel growth driven by VEGF 165A leads to damage in the retina. Anti-VEGF therapies often target this protein to treat these conditions by inhibiting its action on blood vessel formation.
Product promise
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
1 product image
This image is courtesy of Sun Yung, Centro de Investigación Príncipe Felipe.Cell Differentiation - Recombinant human VEGF 165A protein (Active) (ab9571)
Human embryonic stem cells (H9) were differentiated both as embryoid bodies and monolayer cultures (on Matrigel) using a protocol described in Kennedy et al., 2006. BMP-4, FGF-basic (Recombinant human FGF2 protein (Active) ab9596) and VEGF (ab9571) were sequentially added to the media to direct differentiation. These images were taken at day 8, where cell adhesion antigens CD31 (Anti-CD31 antibody ab32457 in green) and CD34 (Anti-CD34 antibody [QBEND/10] ab8536 in red) are abundant and represent primitive haematopoietic cells within the culture. DAPI staining is shown in blue.
Downloads
Product protocols
- Visit the general protocols
- Visit troubleshooting
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com